Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry

Regulatory T cell (Treg)-mediated immunosuppression is considered a major obstacle for successful cancer immunotherapy. The association between clinical outcome and Tregs is being studied extensively in clinical trials, but unfortunately, no consensus has been reached about (a) the markers and (b) t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Immunology, Immunotherapy Jg. 64; H. 10; S. 1271 - 1286
Hauptverfasser: Santegoets, Saskia J. A. M., Dijkgraaf, Eveline M., Battaglia, Alessandra, Beckhove, Philipp, Britten, Cedrik M., Gallimore, Awen, Godkin, Andrew, Gouttefangeas, Cecile, de Gruijl, Tanja D., Koenen, Hans J. P. M., Scheffold, Alexander, Shevach, Ethan M., Staats, Janet, Taskén, Kjetil, Whiteside, Theresa L., Kroep, Judith R., Welters, Marij J. P., van der Burg, Sjoerd H.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Berlin/Heidelberg Springer Berlin Heidelberg 01.10.2015
Springer Nature B.V
Schlagworte:
Animals
Antigens, CD - metabolism
Biomarkers - metabolism
Cancer
Cancer Research
Cell Separation
Cells, Cultured
Clinical trials
Consensus
Cytokines
Female
Flow Cytometry
Forkhead Transcription Factors - metabolism
Humans
Immunology
Immunotherapy
International Cooperation
Ki-67 Antigen - metabolism
Lymphocyte Activation
Lymphocytes
Medical prognosis
Medical research
Medicine
Medicine & Public Health
Monitoring, Immunologic
Oncology
Original
Original Article
Ovarian Neoplasms - immunology
Reference Standards
T-Lymphocytes, Regulatory - immunology
Tumor Escape
Netherlands
United Kingdom > UK
United States > US
Germany
Flow cytometry
Tregs
Consensus
Monitoring
Phenotyping
ISSN:0340-7004, 1432-0851
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Regulatory T cell (Treg)-mediated immunosuppression is considered a major obstacle for successful cancer immunotherapy. The association between clinical outcome and Tregs is being studied extensively in clinical trials, but unfortunately, no consensus has been reached about (a) the markers and (b) the gating strategy required to define human Tregs in this context, making it difficult to draw final conclusions. Therefore, we have organized an international workshop on the detection and functional testing of Tregs with leading experts in the field, and 40 participants discussing different analyses and the importance of different markers and context in which Tregs were analyzed. This resulted in a rationally composed ranking list of “Treg markers”. Subsequently, the proposed Treg markers were tested to get insight into the overlap/differences between the most frequently used Treg definitions and their utility for Treg detection in various human tissues. Here, we conclude that the CD3, CD4, CD25, CD127, and FoxP3 markers are the minimally required markers to define human Treg cells. Staining for Ki67 and CD45RA showed to provide additional information on the activation status of Tregs. The use of markers was validated in a series of PBMC from healthy donors and cancer patients, as well as in tumor-draining lymph nodes and freshly isolated tumors. In conclusion, we propose an essential marker set comprising antibodies to CD3, CD4, CD25, CD127, Foxp3, Ki67, and CD45RA and a corresponding robust gating strategy for the context-dependent analysis of Tregs by flow cytometry.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0340-7004
1432-0851
DOI:10.1007/s00262-015-1729-x